Angiopoietin Concentrations in Diabetic Retinopathy

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 2005 Mar 19

PMID 15774928

Citations 47

Authors

J I Patel

P G Hykin

Z J Gregor

M Boulton

I A Cree

Affiliations

Soon will be listed here.

Abstract

Background/aim: Angiopoietin 1 and 2 interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models. Although VEGF concentrations are elevated, there is little information regarding angiopoietin concentration in the vitreous of patients with diabetic retinopathy.

Methods: Angiopoietin concentrations were measured by luminescence immunoassay in vitreous samples from 17 patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular oedema (CSMO), 10 patients with proliferative diabetic retinopathy (PDR), and five patients with macular hole (controls) obtained at pars plana vitrectomy.

Results: Angiopoietin 1 concentrations were low in patients with macular hole (median 17 pg/ml) while in NPDR with CSMO they were 2002 pg/ml (range 289-5820 pg/ml) and in PDR 186 pg/ml (range 26-2292 pg/ml). Angiopoietin 2 concentrations in NPDR with CSMO were a median of 4000 pg/ml (range 1341-14 329 pg/ml). For both macular hole and PDR patients angiopoietin 2 was below the limit of detection.

Conclusions: Angiopoietin 2 concentration was twice that of angiopoietin 1 in NPDR with CSMO. Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as an anti-permeability agent. The predominance of angiopoietin 2 may allow VEGF induced retinal vascular permeability in patients with CSMO. The relatively low concentration of both angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularisation in cases proceeding to vitrectomy.

Citing Articles

Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists.

Downey L, Sivaprasad S, Chhabra R, Bailey C, Chakrabarti S, Elsherbiny S Eye (Lond). 2024; 38(16):3077-3086.

PMID: 39215141 PMC: 11544140. DOI: 10.1038/s41433-024-03223-w.

Diabetic Retinopathy - Pathophysiology to Treatment: A Review.

Singh R, Walia A, Kaur J, Kumar P, Verma I, Rani N Curr Diabetes Rev. 2024; 21(3):58-67.

PMID: 38315658 DOI: 10.2174/0115733998259940231105200251.

Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice.

Zhang J, Sharma D, Dinabandhu A, Sanchez J, Applewhite B, Jee K J Clin Invest. 2023; 133(13).

PMID: 37227777 PMC: 10313368. DOI: 10.1172/JCI163290.

Towards a New Biomarker for Diabetic Retinopathy: Exploring RBP3 Structure and Retinoids Binding for Functional Imaging of Eyes In Vivo.

Kaushik V, Gessa L, Kumar N, Fernandes H Int J Mol Sci. 2023; 24(5).

PMID: 36901838 PMC: 10002987. DOI: 10.3390/ijms24054408.

Diabetic Retinopathy: Soluble and Imaging Ocular Biomarkers.

Ferrara M, Loda A, Coco G, Grassi P, Cestaro S, Rezzola S J Clin Med. 2023; 12(3).

PMID: 36769560 PMC: 9917666. DOI: 10.3390/jcm12030912.

References

Thurston G, Suri C, Smith K, McClain J, Sato T, Yancopoulos G . Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 2000; 286(5449):2511-4. DOI: 10.1126/science.286.5449.2511. View

Antonetti D, Barber A, Hollinger L, Wolpert E, Gardner T . Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999; 274(33):23463-7. DOI: 10.1074/jbc.274.33.23463. View

Thurston G, Rudge J, Ioffe E, Zhou H, Ross L, Croll S . Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000; 6(4):460-3. DOI: 10.1038/74725. View

Gamble J, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L . Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000; 87(7):603-7. DOI: 10.1161/01.res.87.7.603. View

Koh G, Kim I, Kwak H, Yun M, Leem J . Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp Mol Med. 2002; 34(1):1-11. DOI: 10.1038/emm.2002.1. View

Joussen A, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q . Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol. 2002; 160(5):1683-93. PMC: 1850865. DOI: 10.1016/S0002-9440(10)61115-7. View

Huang D, Swanson E, Lin C, Schuman J, Stinson W, Chang W . Optical coherence tomography. Science. 1991; 254(5035):1178-81. PMC: 4638169. DOI: 10.1126/science.1957169. View

Aiello L, Avery R, Arrigg P, Keyt B, Jampel H, Shah S . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480-7. DOI: 10.1056/NEJM199412013312203. View

Clark J, Grey R, Lim K, Burns-Cox C . Loss of vision before ophthalmic referral in blind and partially sighted diabetics in Bristol. Br J Ophthalmol. 1994; 78(10):741-4. PMC: 504925. DOI: 10.1136/bjo.78.10.741. View

10.

Sato T, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gridley T . Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995; 376(6535):70-4. DOI: 10.1038/376070a0. View

11.

Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H . Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995; 27(1):48-52. DOI: 10.1159/000267567. View

12.

Adamis A, Shima D, Tolentino M, Gragoudas E, Ferrara N, Folkman J . Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996; 114(1):66-71. DOI: 10.1001/archopht.1996.01100130062010. View

13.

Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K . The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996; 74(4):819-25. View

14.

Suri C, Jones P, Patan S, Bartunkova S, Maisonpierre P, Davis S . Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996; 87(7):1171-80. DOI: 10.1016/s0092-8674(00)81813-9. View

15.

Maisonpierre P, Suri C, Jones P, Bartunkova S, Wiegand S, Radziejewski C . Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277(5322):55-60. DOI: 10.1126/science.277.5322.55. View

16.

Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M . Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998; 83(3):233-40. DOI: 10.1161/01.res.83.3.233. View

17.

Mandriota S, Pepper M . Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res. 1998; 83(8):852-9. DOI: 10.1161/01.res.83.8.852. View

18.

do Carmo A, Ramos P, Reis A, Proenca R, Cunha-Vaz J . Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res. 1999; 67(5):569-75. DOI: 10.1006/exer.1998.0546. View

19.

Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y . Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem. 1999; 274(22):15732-9. DOI: 10.1074/jbc.274.22.15732. View

20.

Kim I, Kim H, So J, Kim J, Kwak H, Koh G . Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. Circ Res. 2000; 86(1):24-9. DOI: 10.1161/01.res.86.1.24. View